Ownership and insider activity for Curis, Inc. (CRIS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Price
| Price | $1.12 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $26.0M | $38.3M | $23.6M | $15.4M | $129.6M | $40.0M | $19.7M | $26.7M | $20.0M | $5.1M |
| Short-term Investments | $18.4M | $21.9M | $634000 | $5.1M | $38.9M | $75.9M | $66.0M | $29.7M | 0 | 0 |
| Receivables | $2.5M | $3.1M | $2.9M | $3.2M | $3.0M | $3.2M | $3.0M | $2.8M | $3.3M | 0 |
| Inventory | -$1.3M | 0 | -$827000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $46.9M | $64.3M | $27.1M | $25.0M | $172.8M | $122.4M | $92.1M | $60.9M | $26.4M | $6.9M |
| Property, Plant & Equipment | $413000 | $366000 | $267000 | $303000 | $7.2M | $6.3M | $5.1M | $3.5M | $3.4M | $2.0M |
| Goodwill | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $57.8M | $73.8M | $37.4M | $35.1M | $204.4M | $162.3M | $108.8M | $77.3M | $41.3M | $20.0M |
| Accounts Payable | $5.9M | $5.4M | $2.9M | $4.5M | $4.2M | $6.4M | $3.2M | $3.2M | $3.0M | $5.6M |
| Short-term Debt | $4.9M | $5.9M | $6.9M | 0 | $557000 | 0 | 0 | 0 | 0 | $1.2M |
| Total Current Liabilities | $8.6M | $14.1M | $6.4M | $6.5M | $10.1M | $13.4M | $10.0M | $22.0M | $19.0M | $14.1M |
| Long-term Debt | $14.9M | $35.7M | $28.6M | 0 | $334000 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $28.5M | $49.8M | $41.9M | $69.0M | $73.7M | $71.6M | $62.3M | $57.6M | $47.3M | $14.5M |
| Retained Earnings | -$898.9M | -$952.3M | -$984.8M | -$1.02B | -$1.05B | -$1.09B | -$1.15B | -$1.20B | -$1.24B | -$1.25B |
| Total Equity | $29.3M | $24.0M | -$4.5M | -$33.9M | $130.7M | $90.7M | $46.6M | $19.7M | -$6.0M | $5.5M |
| Total Debt | $19.9M | $41.6M | $35.5M | $166000 | $7.7M | $5.0M | $3.9M | $2.8M | $3.0M | $1.6M |
| Net Debt | -$24.6M | -$18.7M | $11.2M | -$20.4M | -$160.8M | -$110.8M | -$81.7M | -$53.5M | -$17.0M | -$3.4M |
| Working Capital | $38.3M | $50.2M | $20.8M | $18.5M | $162.7M | $108.9M | $82.1M | $38.9M | $7.4M | -$7.2M |
Financial Health
| Debt / Equity | 0.22 |
| Current Ratio | 0.49 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -92.32 |
Profitability
| Return on Equity | -1035.26% |
| Return on Invested Capital | -567.17% |
| Return on Assets | -111.51% |
| Gross Margin | 99.28% |
| Operating Margin | -833.40% |
| Net Margin | -490.33% |
Related companies: ASBP · ATHA · BCTX · CTXR · ENTO · HOTH · ICU
Explore sector: Healthcare · Biotechnology
More sections of CRIS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks